Literature DB >> 8597501

[Transcription factors of the PEA3 group in mammary cancer].

D Monté1, J L Baert, M P Laget, P A Defossez, L Coutte, H Pelczar, I Angeli, F Dewitte, D Stéhelin, Y De Launoit.   

Abstract

Prognosis factors such as mutated or amplified oncogenes are used in the treatment of breast cancer. We have recently shown that the members of the PEA3 group (ER81, ERM and PEA3) from the transcription factor family of the ets genes are overexpressed in breast cancer tumors arising from MMTV-neu transgenic animals. Moreover, we have shown that ER81, and in a lesser extent ERM and PEA3, are not expressed in the estrogen and/or progesterone receptor-positive mammary cancer cell lines, whereas they are expressed in the receptor negative ones. Our research interest in now focused on the role(s) of these oncogenes in the development and the regulation of breast tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8597501

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  1 in total

Review 1.  Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.

Authors:  Natasza A Kurpios; Nancy A Sabolic; Trevor G Shepherd; Gina M Fidalgo; John A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.